A General Immune Boost Instead of a Specific Target

Most cancer immunotherapies rely on identifying and attacking neoepitopes—proteins that arise from mutations specific to a patient’s tumor. This approach works best in cancers with high mutation loads, such as melanoma, but has limited success in tumors with low mutational burden. A study published in Nature Biomedical Engineering and conducted by scientists at the University of Florida challenges that model.

In their experiments, researchers used an experimental mRNA vaccine delivered via lipid nanoparticles, similar to the technology used in COVID-19 vaccines. But instead of encoding a viral protein, this vaccine instructs the immune system to produce proteins that activate an immune response.

One of these proteins, PD-L1, is commonly found on cancer cells and helps them evade immune detection. By artificially inducing PD-L1 expression in tumors, the vaccine made the cancer cells more visible to the immune system, improving the effects of immune checkpoint inhibitors.

Making Resistant Tumors Respond to Treatment

In mouse models of melanoma, the mRNA vaccine cleared drug-resistant tumors and triggered “antigenic spreading”—a process where the immune system begins to recognize and attack multiple tumor-related antigens. In some cases, the vaccine worked even without additional treatments. It was also tested in models of brain, skin, and bone cancers with similarly promising results.

Researchers demonstrated that tumors resistant to checkpoint inhibitors lacked these early immune signals, but became sensitive when treated with RNA-loaded lipid particles that boosted interferon activity. This led to a broader immune reaction, enabling previously unresponsive tumors to respond to immunotherapy.

Together, these results highlight a new paradigm in cancer treatment: instead of customizing a vaccine to match each patient’s unique tumor profile, it may be possible to create a general-purpose vaccine that teaches the immune system to react aggressively to cancer, regardless of the tumor’s specifics.

Laying the Groundwork for an Off-the-Shelf Cancer Vaccine

Dr. Elias Sayour, a pediatric oncologist at the University of Florida and lead investigator on the study, described the results as “a proof of concept” that such a vaccine could eventually become an off-the-shelf solution. Co-author Dr. Duane Mitchell added that this approach may pave the way for more accessible and broadly applicable cancer treatments.

While these findings are based on animal studies, they offer a strong foundation for clinical research. If the vaccine proves effective in humans, it could significantly improve cancer immunotherapy, especially for patients with tumors that previously showed little to no response.

The research not only expands the potential use of mRNA technology beyond infectious disease but also underscores the power of immune system priming. As development continues, a universal cancer vaccine may soon become a powerful tool in the fight against one of the world’s most complex diseases.

[Source]

The post Universal Cancer Vaccine Shows Promise in Boosting Immunotherapy Response appeared first on Medical Journal Daily.

Developed by the British biotech firm Xgenera alongside researchers from the University of Southampton, the test examines microRNA—fragments of genetic material linked to cancer activity. These markers are then processed using AI to detect if cancer is present and where in the body it may be.

A Blood Sample Instead of a Biopsy

For many cancers, diagnosis still depends on methods like colonoscopies or biopsies, which can be stressful and time-consuming. This new approach requires just a small vial of blood. Once analyzed, the AI system can flag the presence of cancer cells with a reported accuracy of over 99%.

The test targets a wide range of cancers including bowel, breast, lung, prostate, pancreatic, and others. This broad reach is one of the reasons it’s being considered as a future screening tool.

Who’s Part of the Trial and What They Hope to Prove

Roughly 8,000 people will take part in the NHS trial—some already showing signs of illness, others not. The idea is to measure the test’s performance across a variety of conditions and confirm how it might work if used more broadly in routine care.

To support its development, the UK government has allocated £2.4 million toward the project. Secretary Wes Streeting, who himself has undergone cancer treatment in the past, early and accurate detection is essential if survival rates are to improve. He called this initiative a step toward speeding up diagnosis and easing the burden on NHS services.

Making It Fast, Scalable, and Cost-Effective

One of the biggest challenges in cancer care is catching the disease early without overwhelming health systems. Known as miONCO-Dx, the blood test could provide a practical alternative to conventional cancer detection methods. It only needs 10 to 15 drops of blood and costs far less than current diagnostic tools—estimated between £120 and £300 per test.

Andy Shapanis, who leads Xgenera, says the real goal is to develop something that could work at a national level. “We’re looking at a tool that can operate at scale without sacrificing accuracy,” he explained. In early tests, the technology performed equally well in detecting early- and late-stage cancers.

Building the Foundation for National Cancer Screening

If the full trial goes well, this test might one day be offered as part of standard NHS checkups. That could significantly cut down on diagnostic delays and reduce the need for more invasive investigations.

Bowel cancer, for example, is among the illnesses this test could detect. While it’s the third most common cancer in the UK, it often goes unnoticed until it’s too late. When diagnosed in its early stages, bowel cancer has a survival rate close to 90%. But if it’s detected late, that rate can fall dramatically to around 10%.

Research and further development will continue at the newly renamed BowelBabe Laboratory at the Francis Crick Institute in London. The facility honors the legacy of Dame Deborah James, who died of bowel cancer in 2022 and raised millions for research before her passing.

This project is also part of a wider national plan to modernize cancer care and make the latest detection technologies more accessible to patients across the UK. As Professor Lucy Chappell of the National Institute for Health and Care Research put it, tools like this bring us closer to faster, easier, and more accurate diagnoses—just when patients need it most.

[Source: 1,2]

The post NHS Trials Blood Test to Detect 12 Common Cancers with Over 99% Accuracy appeared first on Medical Journal Daily.